News Briefs


Animal’s bodybuilding supplement to launch at Walmart

animal pak

Animal is expanding the distribution of its Animal Pak 44 to Walmart stores.

The Animal Pak 44 multivitamin pack contains more than 60-packed nutrients designed to help users achieve optimum body and fitness performance, the company said.

Animal and Walmart are both committed to providing best-in-class products to their customers. This collaboration demonstrates that the quest for fitness is universal. Our expansion to Walmart is the perfect example of our mission to bring world-class sports nutrition to even more consumers, in-store and online,” said Jad Khairallah, senior vice president of marketing of Universal Nutrition.

The launch of the product’s distribution to retail stores follows the brand’s previous launch on the retailer’s website, the company said.


Harvest Snaps intros Selects Baked Navy Bean Snacks

Harvest Snaps Selects Baked Navy Bean Snacks

Harvest Snaps is shaking up the chip aisle with its plant-based Selects Baked Navy Bean Snacks line.

Featuring farm-picked navy beans as the first ingredient, the snacks come in a unique shell shape and are baked, the Fairfield, Calif.-based company said.

Available varieties include:

  • Loaded Taco: It contains zesty spices, cheddar cheese and sour cream;
  • White Cheddar Jalapeño: Featuring creamy white cheddar, it also includes a punch of jalapeño; and
  • Honey Dijon: It includes a pairing of smith and sweet honey with tangy mustard notes.

“We couldn’t be more excited to take our veggie-first philosophy into the salty snack aisle with Harvest Snaps’ Selects Baked Navy Bean Snacks,” said Sandra Payer, head of marketing at Calbee America. “We’ve upped the taste ante in this new lineup while still packing in the protein, so consumers get the best of both worlds – a super tasty chip they can feel good about enjoying.”

Made without artificial flavor or preservatives, and free of wheat, soy, nuts, peanuts and eggs, Selects Baked Navy Bean Snacks are now available for purchase at $4.99.


Enterex Diabetic 16-pack hits Walmart shelves

enterex diabetic strawberry

Enterex Diabetic is expanding the distribution of its nutritional shakes formulated for those with diabetes by debuting a new 16-pack variety in more than 2,800 Walmart stores across the nation.

The brand shared that its shake contains a blend of fibers and slow-digesting carbohydrates that help prevent spikes in blood sugar while also supporting blood sugar management. Enterex Diabetic also contains protein, antioxidants and vitamin D.

Enterex Diabetic’s strawberry shake can be found in 6-packs and now 16-packs in Walmart stores and online.


Lupin to acquire 2 inhalation brands from Sunovion


Lupin has signed an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol, from Sunovion for $75 million.

Lupin expects the transaction to be accretive to earnings in the first year.

The acquisition of these two brands expands Lupin’s portfolio of inhalation products in the United States and strengthens the company’s presence in the respiratory therapy area while continuing to provide patients access to these important medicines.

Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Xopenex HFA is a short-acting beta2-adrenergic agonist indicated for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age or older with reversible obstructive airway disease.

“We remain focused on strengthening our respiratory franchise in the United States,” said Lupin CEO Vinita Gupta. “We have established a strong position in the respiratory segment with our Albuterol MDI and Brovana authorized generic launch. The addition of these two brands enhances our position in the segment.”


FDA OKs new indication for Janssen's Tecvayli

vials of  injectables

Janssen has received the green light from the Food and Drug Administration for Tecvayli (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.

Tecvayli is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment. This off-the-shelf (or ready-to-use) therapy uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen expressed on the surface of multiple myeloma cells and some healthy B-lineage cells.

Tecvayli is Janssen's fourth approved treatment for multiple myeloma.

"We are greatly encouraged by the FDA's approval of teclistamab and Janssen's commitment to the multiple myeloma community," said Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation. "Multiple myeloma is a life-threatening disease with considerable unmet need, and teclistamab is an important new treatment option for patients who have faced multiple relapses."

"Today's achievement, which marks an important addition to our diverse and growing oncology portfolio, strengthens our resolve to discover and develop much-needed cancer treatments for patients and physicians," said Peter Lebowitz, global therapeutic area head, oncology at Janssen research and development. "The approval of Tecvayli, which demonstrated an overall response rate of more than 60% in heavily pretreated patients, underscores our commitment to translate science into medicines as we strive toward our goal of one day eliminating this disease."

"In the pivotal teclistamab study, we have continued to observe positive results in heavily pretreated patients with relapsed or refractory multiple myeloma," said Ajai Chari, professor of medicine, division of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai and study investigator. "As a clinician and researcher, I see first-hand the human toll of this incurable disease. The approval of teclistamab, as the first bispecific antibody in relapsed or refractory multiple myeloma, is a meaningful step in helping many of these hard-to-treat patients."


Dr. Praeger’s expands plant-based Perfect Chick’n line

Dr. Praeger’s Perfect Chick’n

Dr. Praeger’s is growing its all-natural, vegetarian, gluten-free and kosher frozen food options with three new additions to its plant-based Perfect line.

“We are excited to expand our chick’n offerings with three new products we know our consumers will love,” said Ken Krasnow, executive vice president and chief marketing officer at Dr. Praeger’s Sensible Foods. “These new SKUs provide the perfect combination of great taste, health, and variety that Dr. Praeger’s is known for.”

Consumers can find Dr. Praeger’s Perfect Chick’n Tenders, General Tso’s Chick’n and Perfect Nashville Hot Chick’n at such retailers as Publix, ShopRite, Giant, Key Foods, Meijer, Wegmans and Foodtown among others.